New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
06:05 EDTTSROTESARO could trade up 25% with positive data, says Citigroup
Citigroup says TESARO shares are likely to trade up 25% if rolapitant's Phase 3 data meets both the primary and secondary endpoints, which it views as the most likely outcome. Citi says the stock could drop 50% if rolapitant fails in the phase 3 and does not meet the primary endpoint. The firm says it still likes TESARO shares for rolapitant, but believes that niraparib, the company's PARP inhibitor for ovarian and breast cancer, is the real value driving asset that it believes is being largely overlooked.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for TSRO

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use